Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma

Eiju Negoro, Takahiro Yamauchi, Noriko Fukuhara, Kazuhito Yamamoto, Toshiki Uchida, Koji Izutsu, Dai Maruyama, Yasuhito Terui, Hideaki Nakajima, Kiyoshi Ando, Youko Suehiro, Ilseung Choi, Nobuhiro Kanemura, Nobuhiko Nakamura, Go Yamamoto, Yoshinobu Maeda, Hirohiko Shibayama, Fumiko Nagahama, Yusuke Sonehara, Hirokazu NagaiHwei Fang Tien, Yok Lam Kwong, Won Seog Kim, Kensei Tobinai

研究成果査読

2 被引用数 (Scopus)

抄録

A Japanese subgroup analysis from the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) was performed to evaluate the efficacy and safety outcomes of the Japanese population. In this Asian phase II study, darinaparsin was administered to 65 patients, including 37 Japanese patients. In the Japanese population, the histopathological type of PTCL was PTCL, not otherwise specified in 26 patients (70.3%), angioimmunoblastic T-cell lymphoma in 9 patients (24.3%) and anaplastic large cell lymphoma, anaplastic lymphoma kinase (ALK)-negative in 2 patients (5.4%), and the median patient age was 70.0 (range: 43-85). 94.6% and 35.1% of the Japanese population had previously received multi-agent and single-agent regimen, respectively. The efficacy and safety were summarized and compared between the overall and Japanese populations. Based on central assessment, the overall response rate was 22.2% (8/36; 90% confidence interval [CI]: 11.6-36.5) in the Japanese population and 19.3% (11/57; 90% CI: 11.2-29.9) in the overall population. There were no essential differences in the safety profile of darinaparsin between the Japanese population and the overall population. The results of this subgroup analysis indicate that the efficacy and safety profiles of the Japanese subpopulation were broadly consistent with that of the overall population, and that darinaparsin is potentially an effective treatment with a manageable safety profile in Japanese patients with relapse or refractory PTCL.

本文言語English
ページ(範囲)108-120
ページ数13
ジャーナルJournal of Clinical and Experimental Hematopathology
63
2
DOI
出版ステータスPublished - 2023
外部発表はい

ASJC Scopus subject areas

  • 医学一般

フィンガープリント

「Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル